Moncef Zouali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6331674/publications.pdf

Version: 2024-02-01

104 papers 2,974 citations

30 h-index 197818 **49** g-index

126 all docs

126 docs citations

126 times ranked 2865 citing authors

#	Article	IF	CITATIONS
1	DNA methylation signatures of autoimmune diseases in human B lymphocytes. Clinical Immunology, 2021, 222, 108622.	3.2	21
2	B lymphocytes, the gastrointestinal tract and autoimmunity. Autoimmunity Reviews, 2021, 20, 102777.	5.8	10
3	Epigenetics of Autoimmune Diseases. , 2020, , 429-466.		1
4	Targeting a cysteine protease from a pathobiont alleviates experimental arthritis. Arthritis Research and Therapy, $2020, 22, 114$.	3 . 5	10
5	Editorial: Innate Immunity Pathways in Autoimmune Diseases. Frontiers in Immunology, 2019, 10, 1245.	4.8	8
6	The Interplay Between Innate-Like B Cells and Other Cell Types in Autoimmunity. Frontiers in Immunology, 2018, 9, 1064.	4.8	35
7	"B cells and autoimmunity 2016― Autoimmunity, 2017, 50, 1-3.	2.6	4
8	Mechanisms That Shape Human Antibody Repertoire Development in Mice Transgenic for Human Ig H and L Chain Loci. Journal of Immunology, 2017, 198, 3963-3977.	0.8	20
9	The emerging roles of B cells as partners and targets in periodontitis. Autoimmunity, 2017, 50, 61-70.	2.6	54
10	Developing Connections among B Lymphocytes and Deregulated Pathways in Autoimmunity. Molecular Medicine, 2016, 22, 705-712.	4.4	5
11	B cells and Autoimmunity 2013. Molecular Immunology, 2014, 62, 265.	2.2	0
12	The Dopaminergic System in Autoimmune Diseases. Frontiers in Immunology, 2014, 5, 117.	4.8	125
13	Epigenetics and Autoimmune Diseases. , 2014, , 381-401.		2
14	Transcriptional and metabolic pre-B cell receptor-mediated checkpoints: Implications for autoimmune diseases. Molecular Immunology, 2014, 62, 315-320.	2.2	20
15	Tight relationships between B lymphocytes and the skeletal system. Trends in Molecular Medicine, 2014, 20, 405-412.	6.7	49
16	Distorted expression of dopamine receptor genes in systemic lupus erythematosus. Immunobiology, 2013, 218, 979-983.	1.9	34
17	The epigenetic landscape of B lymphocyte tolerance to self. FEBS Letters, 2013, 587, 2067-2073.	2.8	13
18	Belimumab Therapy in Systemic Lupus Erythematosus. BioDrugs, 2013, 27, 225-235.	4.6	8

#	Article	lF	Citations
19	Corruption of Human Follicular B-Lymphocyte Trafficking by a B-Cell Superantigen. Molecular Medicine, 2012, 18, 636-646.	4.4	0
20	Marginal Zone B-Cells, a Gatekeeper of Innate Immunity. Frontiers in Immunology, 2011, 2, 63.	4.8	84
21	Epigenetics in lupus. Annals of the New York Academy of Sciences, 2011, 1217, 154-165.	3.8	48
22	The potential role of VPREB1 gene copy number variation in susceptibility to rheumatoid arthritis. Molecular Immunology, 2011, 48, 1338-1343.	2.2	24
23	Preface. Molecular Immunology, 2011, 48, 1279-1280.	2.2	1
24	The Multi-faceted Influences of Estrogen on Lymphocytes: Toward Novel Immuno-interventions Strategies for Autoimmunity Management. Clinical Reviews in Allergy and Immunology, 2011, 40, 16-26.	6.5	52
25	In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. Journal of Biomedical Science, 2010, 17, 51.	7.0	22
26	Functional imaging in the immune system. European Journal of Immunology, 2009, 39, 7-10.	2.9	1
27	A Novel Tissue Engineeringâ€based Assay for Immunological Infertility. Scandinavian Journal of Immunology, 2008, 68, 463-468.	2.7	3
28	Toxicogenomics â€" A novel opportunity to probe lupus susceptibility and pathogenesis. International Immunopharmacology, 2008, 8, 1330-1337.	3.8	8
29	Receptor editing and receptor revision in rheumatic autoimmune diseases. Trends in Immunology, 2008, 29, 103-109.	6.8	27
30	Cellular interactions and signalling defects in lupus (1). Lupus, 2008, 17, 236-240.	1.6	3
31	B lymphocytes - chief players and therapeutic targets in autoimmune diseases. Frontiers in Bioscience - Landmark, 2008, Volume, 4852.	3.0	26
32	B-cell Dysfunctions in Autoimmune Diseases. , 2008, , 377-384.		0
33	Novel Opportunities for Therapeutic Targeting in Systemic Autoimmune Diseases., 2007, 361, 285-298.		6
34	Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6317-6322.	7.1	81
35	Direct impact of inactivated HIV-1 virions on B lymphocyte subsets. Molecular Immunology, 2007, 44, 2124-2134.	2.2	11
36	B Cell Superantigens Subvert Innate Functions of B Cells. , 2007, 93, 92-105.		16

#	Article	IF	Citations
37	Exploitation of Host Signaling Pathways by B Cell SuperantigensPotential Strategies for Developing Targeted Therapies in Systemic Autoimmunity. Annals of the New York Academy of Sciences, 2007, 1095, 342-354.	3.8	7
38	Pathogenic autoantibodies: Emerging insights into tissue injury. Immunology Letters, 2006, 103, 17-26.	2.5	38
39	Unscrambling the role of human parvovirus B19 signaling in systemic autoimmunity. Biochemical Pharmacology, 2006, 72, 1453-1459.	4.4	27
40	B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets, 2006, 10, 803-815.	3.4	14
41	Crippled B Lymphocyte Signaling Checkpoints in Systemic Autoimmunity. , 2005, , 227-243.		0
42	Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunology Letters, 2005, 101, 123-143.	2.5	101
43	Taming Lupus. Scientific American, 2005, 292, 70-77.	1.0	17
44	Immune receptor signaling, aging, and autoimmunity. Cellular Immunology, 2005, 233, 102-108.	3.0	74
45	Staphylococcal Protein A Deletes B-1a and Marginal Zone B Lymphocytes Expressing Human Immunoglobulins: An Immune Evasion Mechanism. Journal of Immunology, 2005, 175, 7719-7727.	0.8	30
46	Effect of the B cell superantigen protein A from S. aureus on the early lupus disease of (NZB×NZW) F1 mice. Molecular Immunology, 2005, 42, 849-855.	2.2	22
47	B-lymphocytes, innate immunity, and autoimmunity. Clinical Immunology, 2005, 114, 17-26.	3.2	146
48	Taming lupus. Scientific American, 2005, 292, 58-65.	1.0	2
49	Specific In Vivo Deletion of B-Cell Subpopulations Expressing Human Immunoglobulins by the B-Cell Superantigen Protein L. Infection and Immunity, 2004, 72, 3515-3523.	2.2	24
50	B Lymphocyte Selection and Survival in Systemic Lupus. International Archives of Allergy and Immunology, 2004, 133, 72-83.	2.1	8
51	Down-modulation of the antigen receptor by a superantigen for human B cells. Immunology Letters, 2004, 92, 91-96.	2.5	16
52	B lymphocyte signaling pathways in systemic autoimmunity: Implications for pathogenesis and treatment. Arthritis and Rheumatism, 2004, 50, 2730-2741.	6.7	65
53	Probing the Specificity of Human Myeloma Proteins with a Random Peptide Phage Library. Scandinavian Journal of Immunology, 2003, 57, 583-590.	2.7	11
54	Subversion of B lymphocyte signaling by infectious agents. Genes and Immunity, 2003, 4, 95-103.	4.1	21

#	Article	IF	Citations
55	The human antibody repertoire to infectious agents: implications for disease pathogenesis. Molecular lmmunology, $2003, 40, 1-11$.	2.2	27
56	B cell diversity and longevity in systemic autoimmunity. Molecular Immunology, 2002, 38, 895-901.	2.2	35
57	Receptor Revision and Systemic Lupus. Scandinavian Journal of Immunology, 2002, 55, 425-431.	2.7	18
58	Molecular determinants of the human antibody response to HIV-1: implications for disease control. Journal of Clinical Immunology, 2001, 21, 410-419.	3.8	12
59	B cell receptor signaling and autoimmunity. FASEB Journal, 2001, 15, 2085-2098.	0.5	82
60	Expression of B Cell Receptor-Associated Signaling Molecules in Human Lupus. Autoimmunity, 2001, 33, 213-224.	2.6	67
61	Tracking Immunoglobulin Variable-Gene Expression in HIV Infection. Applied Biochemistry and Biotechnology, 2000, 83, 13-30.	2.9	3
62	Abnormal DNA methylation and deoxycytosineâ€deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB Journal, 1999, 13, 1415-1422.	0.5	55
63	High-density Expression of CD95 on B Cells and Underrepresentation of the B-1 Cell Subset in Human Lupus. Journal of Autoimmunity, 1998, 11, 449-455.	6.5	17
64	Signaling in human lupus T lymphocytes. Lupus, 1998, 7, 499-502.	1.6	7
65	Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB Journal, 1998, 12, 1473-1480.	0.5	29
66	Polymorphism of the Human Immunoglobulin Heavy Chain Locus in Rheumatoid Arthritis. Autoimmunity, 1997, 25, 109-116.	2.6	5
67	The Structure of Human Lupus Anti-DNA Antibodies. Methods, 1997, 11, 27-35.	3.8	18
68	Identification of the B cell superantigen-binding site of HIV-1 gp120. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1356-1360.	7.1	86
69	Expression of the Tyrosine Kinase Lyn during B Cell Receptor Engagement and Apoptosis. Annals of the New York Academy of Sciences, 1997, 815, 122-123.	3.8	3
70	Probing Human Antibody Diversity in HIV Infection. , 1997, , 293-301.		0
71	Receptor Editing, Immune Diversification, and Self-Tolerance. Immunity, 1996, 5, 505-511.	14.3	182
72	DNA Methylation: A Potential Pathway to Abnormal Autoreactive Lupus B Cells. Clinical Immunology and Immunopathology, 1996, 80, 1-8.	2.0	23

#	Article	IF	Citations
73	Nonrandom features of the human immunoglobulin variable region gene repertoire expressed in response to HIV-1. Applied Biochemistry and Biotechnology, 1996, 61, 149-155.	2.9	5
74	Idiotype Manipulation for Autoimmune Diseases: Where Are We Going?. Autoimmunity, 1996, 24, 55-63.	2.6	7
75	Selective variationsin vivo of VH3 and VH1 gene family expression in peripheral B cell IgM, IgD and IgG during HIV infection. European Journal of Immunology, 1995, 25, 1524-1528.	2.9	44
76	Molecular characterization of human monoclonal antibodies specific for several HIV proteins: analysis of the VH3 family expression. Immunology Letters, 1995, 47, 107-112.	2.5	15
77	Analysis of human V H gene repertoire expression in peripheral CD19+ B cells. Immunogenetics, 1995, 42, 342-52.	2.4	32
78	B-cell superantigens: implications for selection of the human antibody repertoire. Trends in Immunology, 1995, 16, 399-405.	7.5	99
79	Detection of Human Variable Gene Family Expression at the Single-Cell Level. , 1995, 51, 99-110.		0
80	Variable region light chain genes encoding human antibodies to HIV-1. Molecular Immunology, 1995, 32, 77-88.	2.2	19
81	Human Pathogenic Autoantibodies and Their Escape from Deletion ^a . Annals of the New York Academy of Sciences, 1995, 764, 436-439.	3.8	2
82	Anti-Idiotypic Antibodies to the Third Variable Domain of gp120 Induce an Anti-HIV-1 Antibody Response in Mice. Virology, 1994, 200, 176-188.	2.4	8
83	Human autoantibodies and their genes. Applied Biochemistry and Biotechnology, 1994, 47, 135-142.	2.9	1
84	Unravelling antibody genes. Nature Genetics, 1994, 7, 118-120.	21.4	22
85	The heavy chain variable region genes of human lupus autoantibodies. , 1994, , 131-149.		0
86	The Molecular Biology of Anti-DNA Antibodies and their Idiotopes. Lupus, 1992, 1, 325-331.	1.6	2
87	Development of Human Antibody Variable Genes in Systemic Autoimmunity. Immunological Reviews, 1992, 128, 73-99.	6.0	45
88	Cloning of a gene encoding a lupus-associated human autoantibody VK region using the polymerase chain reaction and degenerate primers. Gene, 1991, 101, 305-306.	2.2	6
89	UV-treated polystyrene microtitre plates for use in an ELISA to measure antibodies against synthetic peptides. Journal of Immunological Methods, 1991, 142, 73-82.	1.4	41
90	Quantitative clonal analysis of the B cell repertoire in human lupus. Cellular Immunology, 1991, 133, 161-177.	3.0	17

#	Article	IF	CITATIONS
91	Anti-idiotypic antibodies to human anti-gp120 antibodies bind recombinant and cellular human CD4. European Journal of Immunology, 1991, 21, 743-751.	2.9	25
92	Organization of the immunoglobulin heavy chain variable region gene complex in human lupus. Immunogenetics, 1990, 32, 451-5.	2.4	5
93	Idiotype-mediated intervention in systemic lupus erythematosus. Journal of Autoimmunity, 1990, 3, 381-388.	6.5	14
94	Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. Journal of Autoimmunity, 1990, 3, 393-414.	6.5	51
95	FROM IDIOTYPIC EXPRESSION OF LUPUS ANTI-DNA ANTIBODIES TO DIVERSIFICATION OF Ig VARIABLE REGION GENES. , 1990, , 73-89.		0
96	Restriction fragment length polymorphism analysis of the VX locus in human lupus. European Journal of Immunology, 1989, 19, 1757-1760.	2.9	26
97	Nucleic acid-binding specificity and idiotypic expression of canine anti-DNA antibodies. European Journal of Immunology, 1988, 18, 923-927.	2.9	12
98	Origin and Diversification of Anti-DNA Antibodies. Immunological Reviews, 1988, 105, 137-160.	6.0	64
99	Murine lupus anti-DNA antibodies cross-react with the hapten (4-hydroxy-5-iodo-3-nitrophenyl)acetyl, but immunization-induced anti-DNA antibodies do not. European Journal of Immunology, 1987, 17, 509-513.	2.9	18
100	A rapid ELISA for measurement of antibodies to nucliec acid antigens using UV-treated polystyrene microplates. Journal of Immunological Methods, 1986, 90, 105-110.	1.4	69
101	ldiotype restriction in human autoantibodies to DNA in systemic lupus erythematosus. Immunology Letters, 1984, 7, 187-190.	2.5	48
102	Anti-DNA autoantibody activity and idiotypic relationships of human monoclonal proteins. European Journal of Immunology, 1984, 14, 1085-1089.	2.9	45
103	Antibodies to heterogeneous nuclear ribonucleoproteins in sera from patients with rheumatic autoimmune diseases. Journal of Clinical Immunology, 1984, 4, 209-219.	3.8	11
104	Evaluation of auto-antibodies in chronic mucocutaneous candidiasis without endocrinopathy. Mycopathologia, 1984, 84, 87-93.	3.1	11